Researchers studied growth and puberty in a multinational prospective cohort of children with juvenile dermatomyositis.
A triple steroid/intravenous immunoglobulin/steroid-sparing immunosuppressant induction strategy was effective for the treatment of statin-induced anti-HMGCR myopathy.
Researchers analyzed endothelial biomarker levels in the peripheral blood of patients with juvenile dermatomyositis and their association with disease assessments.
Researchers measured discordance between patient or family and physician global activity scores in juvenile dermatomyositis, and determined factors associated with discordance.
Muscle disease is more prominent among patients with dermatomyositis and anti-Mi2 autoantibodies compared with in those who have anti-Mi2-negative dermatomyositis.
Researchers studied the role of individual determinants of ultraviolet radiation exposure prior to dermatomyositis diagnosis.
Jemima Albayda, MD, discusses the cardiac complications in idiopathic inflammatory myopathies.
Investigators sought to determine whether patients with cutaneous lupus erythematosus have a similar frequency of antimalarial adverse cutaneous drug eruptions to patients with dermatomyositis.
One-third of patients with refractory anti-HMGCR antibodies had improved strength or other evidence of improved disease activity after rituximab treatment.
The signs and symptoms associated with disease activity in juvenile dermatomyositis could be used to stratify patients and adapt treatment plans.